Researchers develop antibodies targeting ion channel hTRPV1, important for pain therapy

In a research article, published on April 16 in Science Advances, researchers from Oblique Therapeutics AB together with…

Read more
19 Apr 2021

Årsstämma 2021

English version follows below. Med anledning av den fortsatta smittspridningen av viruset som orsakar covid-19 kommer Fluicells årsstämma…

Read more
16 Apr 2021

CEO Newsletter 3, 2021

”Retreading old footsteps has never been a driving force for Fluicell” In the third issue of the CEO…

Read more
30 Mar 2021

Fluicell launches Biozone 6

We are launching Biozone 6, Fluicell’s new innovation for single-cell pharmacology that lets you perform drug testing and…

Read more
15 Mar 2021

Biopixlar advances: Towards printing heart cells

Biopixlar’s microfluidic technology is ideal for printing even the most sensitive cell types. Using cells received from Dr….

Read more
12 Mar 2021

Fluicell in Di Hållbart Näringsliv

“Building human tissues cell by cell”. In an interview with Di Hållbart Näringsliv, Fluicell’s CEO Victoire Viannay talks…

Read more
09 Mar 2021

Biopixlar in 3D bioprinting eBook

“Biopixlar is a high-resolution bioprinting platform that uses a proprietary molecular cell-binding process and open volume microfluidics technology…

Read more
04 Mar 2021

Biozone 6™ launches March 15

Biozone 6™ is a new concept for direct single-cell pharmacology from Fluicell that lets users generate dose-response curves…

Read more
01 Mar 2021

CEO Newsletter 2, 2021

“2020 was a challenging but very successful year for Fluicell. In 2021, it is time to really pick…

Read more
24 Feb 2021